LUMPUR, 28 AUGUST 2020 – Ho Wah Genting Berhad (“HWGB”
or the “Company”) (KLSE:9601), today announced that the United States
Food and Drug Administration (“FDA”) has responded to the second communication
to its Joint Ventured US-based E-Mo Biology Inc. (“EBI”) with FDA by requesting
EBI to provide further information on the Investigational New Drug (“IND”)
application which proposes the use of existing poliomyelitis virus vaccines
(“polio vaccines”) for prevention of COVID-19.
Company had, on 14 August 2020, through wholly-owned subsidiary HWGB Biotech
Sdn Bhd (“HWGB Biotech”) signed a joint venture agreement with EBI for the research and development (“R&D”)
of vaccines, immunological treatment and diagnostic product development in
relation to the COVID-19 virus, following the Memorandum of Agreement signed on
06 August 2020.
recap, under the JV, EBI is also responsible for R&D, testing, registration
and commercialisation of five provisional patent applications and other
applications related to the patents, which EBI owns.
ABOUT HO WAH GENTING
Ho Wah Genting Berhad (“HWGB” or the “Company”) is
principally engaged in investment holdings and the provision of management
services to its subsidiaries. The Company had on 30 June 2020 diversified its
existing businesses to include healthcare related industry which mainly
involved in Health Supplement, Biotechnology and Health Technology. In addition,
the Company and its subsidiaries (“HWGB Group” or the “Group”)
are also engaging in the businesses of Investment holdings; manufacturing of
wires and cables and moulded power supply cord sets and cable assemblies for
electrical and electronic devices and equipment; Trading of wires and cables;
and travel agent and tour related services.
ABOUT E-MO BIOLOGY INC.
E-Mo Biology Inc (“EBI”)
was incorporated in the state of California in the United States of America on
24 May 2020. It is principally involved in conducting biology research and
development activities and is the sponsor of a study which indicates booster
polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Xie QiYi, who serves as its Managing
Director of EBI. He has over 30 years of experiences in areas of public health
and infection disease control. He was also involved in the development of medical
and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs
for quality systems.